dc.contributor.author | Johansen, Silje | |
dc.contributor.author | Blomberg, Bjørn | |
dc.contributor.author | Vo, Anh Khoi | |
dc.contributor.author | Wendelbo, Øystein | |
dc.contributor.author | Reikvam, Håkon | |
dc.date.accessioned | 2023-01-02T10:24:19Z | |
dc.date.available | 2023-01-02T10:24:19Z | |
dc.date.created | 2022-09-28T11:24:20Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1465-3249 | |
dc.identifier.uri | https://hdl.handle.net/11250/3040250 | |
dc.description.abstract | Background aims
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for patients with hematological malignancies; however, allo-HSCT does not come without the cost of treatment-related morbidity and mortality. Early detection of risk factors could be helpful in identifying patients who could benefit from early interventions. Many patients gain weight during the allo-HSCT treatment, although little is known about the impact of weight gain.
Methods
Weight gain in 146 consecutively enrolled adult patients undergoing allo-HSCT was explored.
Results
In total, 141 patients (97%) gained weight along the course of allo-HSCT. Median weight increase was 4.8 kg (range 0.0–16.1 kg), with median increase in body weight 6.5% (range 0.0%–30.8%). Maximum weight increase was observed at day +7 (range day –8, +44). Weight gain was associated with increased incidence of acute graft-versus-host disease. Patients with weight gain >10% had a significantly greater 5-year mortality compared with those with lower weight gain (P = 0.031, rank sum test).
Conclusions
Weight gain is a simple variable with the ability to provide prognostic information for patients undergoing allo-HSCT. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Weight gain during treatment course of allogenic hematopoietic stem cell transplantation in patients with hematological malignancies affects treatment outcome | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 The Author(s) | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.doi | 10.1016/j.jcyt.2022.08.006 | |
dc.identifier.cristin | 2056274 | |
dc.source.journal | Cytotherapy | en_US |
dc.source.pagenumber | 1190-1194 | en_US |
dc.identifier.citation | Cytotherapy. 2022, 24 (12), 1190-1194. | en_US |
dc.source.volume | 24 | en_US |
dc.source.issue | 12 | en_US |